| Feasibility of an Enhanced Symptom Monitoring and Expedited Subspecialty Care Referral Intervention to Improve Side Effect Management for Patients With Melanoma Receiving an Immune Checkpoint Inhibitor (NCT07660666) | OHSU Knight Cancer Institute | 2026-11-01 |
| Mammogram Pretreatment With Ulipristal Acetate (NCT07434128) | OHSU Knight Cancer Institute | 2026-08-31 |
| An Exercise Intervention for Improving Mental and Physical Health in Patients With Primary Brain Tumors and Their Caregivers, ET-NEURO Trial (NCT07278440) | OHSU Knight Cancer Institute | 2026-07-10 |
| A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatment of Chronic Pancreatitis and Benign Pancreatic Tumors (NCT05453851) | OHSU Knight Cancer Institute | 2026-07-01 |
| 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer (NCT04529044) | OHSU Knight Cancer Institute | 2026-06-30 |
| Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial (NCT07726602) | OHSU Knight Cancer Institute | 2026-06-29 |
| Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study (NCT07405086) | OHSU Knight Cancer Institute | 2026-06-08 |
| Phase I Randomized Controlled Trial of Functional Resistance Training in Older Cancer Survivors: The ACES Trial (NCT07606313) | OHSU Knight Cancer Institute | 2026-05-18 |
| Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation (NCT07548983) | OHSU Knight Cancer Institute | 2026-04-21 |
| GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer (NCT07504835) | OHSU Knight Cancer Institute | 2026-04-15 |
| A Tailored, Web-based Program (COMPASS) to Improve Exercise and Dietary Changes in Stage I-III Pancreatic Cancer Patients Receiving Neoadjuvant Chemotherapy (NCT07651358) | OHSU Knight Cancer Institute | 2026-04-15 |
| Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma (NCT07511504) | OHSU Knight Cancer Institute | 2026-04-02 |
| Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT (NCT07498517) | OHSU Knight Cancer Institute | 2026-02-28 |
| OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (NCT07089940) | OHSU Knight Cancer Institute | 2026-01-27 |
| Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia (NCT07228273) | OHSU Knight Cancer Institute | 2025-12-12 |
| A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer (NCT06630325) | OHSU Knight Cancer Institute | 2025-06-24 |
| Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome (NCT06895473) | OHSU Knight Cancer Institute | 2025-06-04 |
| Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial (NCT06357676) | OHSU Knight Cancer Institute | 2025-05-29 |
| Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer (NCT06528210) | OHSU Knight Cancer Institute | 2025-04-16 |
| Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment (NCT06784167) | OHSU Knight Cancer Institute | 2025-03-10 |
| Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML (NCT06504459) | OHSU Knight Cancer Institute | 2025-01-03 |
| Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial (NCT06673095) | OHSU Knight Cancer Institute | 2024-12-11 |
| BEST-RPP Pilot: Screening for Esophageal Cancer in Rural Oregon Without an Endoscopy (NCT06335966) | OHSU Knight Cancer Institute | 2024-09-11 |
| Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA, IIB, or IIIA Melanoma (NCT06157099) | OHSU Knight Cancer Institute | 2024-09-01 |
| Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia (NCT06357182) | OHSU Knight Cancer Institute | 2024-08-22 |
| Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma (NCT06398587) | OHSU Knight Cancer Institute | 2024-08-01 |
| Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer (NCT05705492) | OHSU Knight Cancer Institute | 2024-07-17 |
| Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy (NCT05919329) | OHSU Knight Cancer Institute | 2024-06-25 |
| Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer (NCT06067438) | OHSU Knight Cancer Institute | 2024-06-21 |
| Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma (NCT06249191) | OHSU Knight Cancer Institute | 2024-06-13 |
| CREATE: Art for Children With Cancer (NCT06342453) | OHSU Knight Cancer Institute | 2024-06-04 |
| Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors (NCT06320405) | OHSU Knight Cancer Institute | 2024-05-21 |
| Use Of Indocyanine Green In Pancreas Surgery (NCT06084013) | OHSU Knight Cancer Institute | 2024-05-17 |
| EMBRACE: Exercising Together (NCT06049355) | OHSU Knight Cancer Institute | 2024-04-18 |
| An Exercise Prehabilitation Intervention for Improving Mobility and Recovery Outcomes in Patients Undergoing Head and Neck Cancer Surgery (NCT06079697) | OHSU Knight Cancer Institute | 2024-02-01 |
| StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or Head and Neck Cancer Patients (NCT05073172) | OHSU Knight Cancer Institute | 2024-01-01 |
| Y-90 Versus SBRT for Inoperable HCC (NCT05157451) | OHSU Knight Cancer Institute | 2023-12-01 |
| Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET (NCT05722925) | OHSU Knight Cancer Institute | 2023-10-04 |
| Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (NCT05943496) | OHSU Knight Cancer Institute | 2023-10-02 |
| At-Home Dermoscopy Artificial Intelligence (NCT05321784) | OHSU Knight Cancer Institute | 2023-09-27 |
| Observational Study of Sex Differences in Symptoms During Immune Checkpoint Inhibitor Treatment for People With Cancer (NCT06562777) | OHSU Knight Cancer Institute | 2023-09-15 |
| ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer (NCT05368506) | OHSU Knight Cancer Institute | 2023-07-30 |
| Electronic Quitline Referral With Enhanced Academic Detailing for the Promotion of Smoking Cessation (NCT04969978) | OHSU Knight Cancer Institute | 2023-06-20 |
| Feasibility of OmnEcoil System for Integrated Endorectal MRI and Transrectal MRI-Targeted Biopsy of the Prostate (NCT05362032) | OHSU Knight Cancer Institute | 2023-05-08 |
| Enhancing Skin Cancer Early Detection and Treatment in Primary Care (NCT05675709) | OHSU Knight Cancer Institute | 2023-04-25 |
| Use of Virtual Reality Goggles During Chemotherapy Infusion to Reduce Anxiety-Related Symptoms (NCT05793957) | OHSU Knight Cancer Institute | 2023-04-20 |
| Oxygen-Enhanced MRI for Generating Hypoxia Maps in Patients With Intracranial Tumors (NCT05904704) | OHSU Knight Cancer Institute | 2023-04-12 |
| Impact of Dietary Fiber Supplementation on Colonic Microbiome (NCT05643859) | OHSU Knight Cancer Institute | 2023-04-01 |
| Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy (NCT04965311) | OHSU Knight Cancer Institute | 2023-03-01 |
| SMMART Adaptive Clinical Treatment (ACT) Trial (NCT05238831) | OHSU Knight Cancer Institute | 2023-01-30 |
| The Use of "Smart" Body-Weight Scales for Weight and Nutritional Monitoring in Patients With Head and Neck Cancer Undergoing Radiation Therapy (NCT05457478) | OHSU Knight Cancer Institute | 2023-01-13 |
| Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma (NCT05327738) | OHSU Knight Cancer Institute | 2022-12-10 |
| Improving Decision-Making Encounters in Lung Cancer Using a Low-Literacy Conversation Tool (NCT05407168) | OHSU Knight Cancer Institute | 2022-10-31 |
| Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia (NCT05396859) | OHSU Knight Cancer Institute | 2022-10-28 |
| MammoScreen Breast Cancer Risk Assessment and Decision Aid for Breast Cancer Screening and Referrals (NCT04996316) | OHSU Knight Cancer Institute | 2022-09-07 |
| Evaluating the Human Papillomavirus Self-Collection Experience in Individuals Who Have Experienced Sexual Trauma (NCT05458869) | OHSU Knight Cancer Institute | 2022-09-06 |
| Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia (NCT04872790) | OHSU Knight Cancer Institute | 2022-09-02 |
| Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer (NCT05034627) | OHSU Knight Cancer Institute | 2022-08-09 |
| Humidified Forest Oils for Immune System Recovery in Stage I-III Breast or Prostate Cancer (NCT05012813) | OHSU Knight Cancer Institute | 2022-07-19 |
| Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma (NCT04850599) | OHSU Knight Cancer Institute | 2022-06-14 |
| Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study (NCT04993313) | OHSU Knight Cancer Institute | 2022-03-18 |
| Effects of Simulated Solar Radiation on Human Skin in Preventing Skin Cancer (NCT05027009) | OHSU Knight Cancer Institute | 2021-11-18 |
| Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer (NCT05081024) | OHSU Knight Cancer Institute | 2021-09-03 |
| A Digital Intervention Protocol to Enhance Recovery After Head and Neck Surgery (NCT04814524) | OHSU Knight Cancer Institute | 2021-07-01 |
| Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer (NCT04481113) | OHSU Knight Cancer Institute | 2021-06-07 |
| NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer (NCT04539808) | OHSU Knight Cancer Institute | 2021-05-27 |
| Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC (NCT04890054) | OHSU Knight Cancer Institute | 2021-05-14 |
| Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year (NCT04455958) | OHSU Knight Cancer Institute | 2021-05-01 |
| Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy (NCT04465760) | OHSU Knight Cancer Institute | 2021-02-25 |
| Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (NCT04659616) | OHSU Knight Cancer Institute | 2021-01-14 |
| Predicting the Impact of Treatment Toxicities on Health During Cancer ( PATTERN ) (NCT05790538) | OHSU Knight Cancer Institute | 2020-10-22 |
| Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer (NCT04400903) | OHSU Knight Cancer Institute | 2020-09-21 |
| Decision Aid for the Improvement of Decision-Making in Patients With Non-small Cell Lung Cancer (NCT04946279) | OHSU Knight Cancer Institute | 2020-08-07 |
| Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma (NCT03613259) | OHSU Knight Cancer Institute | 2020-06-01 |
| Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer (NCT04267887) | OHSU Knight Cancer Institute | 2020-05-11 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (NCT03878524) | OHSU Knight Cancer Institute | 2020-04-01 |
| Identifying and Caring for Individuals With Inherited Cancer Syndrome (NCT04494945) | OHSU Knight Cancer Institute | 2020-03-09 |
| TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer (NCT04104139) | OHSU Knight Cancer Institute | 2019-12-11 |
| Hyperspectral Endoscopy Imaging for the Early Detection of Precancerous Lesions in Average Risk Patients (NCT04172493) | OHSU Knight Cancer Institute | 2019-08-26 |
| Whole Body Vibration for the Improvement of Health and Functioning in Participants With Chemotherapy-Induced Peripheral Neuropathy (NCT04170075) | OHSU Knight Cancer Institute | 2019-08-05 |
| Targeted Pathway Inhibition in Patients With Pancreatic Cancer (NCT04005690) | OHSU Knight Cancer Institute | 2019-08-01 |
| Progressive Resistance Training for the Improvement of Physical Function (NCT04247425) | OHSU Knight Cancer Institute | 2019-06-28 |
| Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer (NCT03995667) | OHSU Knight Cancer Institute | 2019-06-11 |
| Feasibility of FMISO in Brain Tumors (NCT03649880) | OHSU Knight Cancer Institute | 2019-06-01 |
| War on Melanoma™ Public Health & Education Campaign (NCT04611568) | OHSU Knight Cancer Institute | 2019-05-14 |
| Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma (NCT03960177) | OHSU Knight Cancer Institute | 2019-03-27 |
| Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer (NCT03812289) | OHSU Knight Cancer Institute | 2019-02-07 |
| GET FIT Prostate: A Randomized Controlled Exercise Trial (NCT03741335) | OHSU Knight Cancer Institute | 2019-02-05 |
| EXERCISING TOGETHER for Couples Coping With Cancer (NCT03630354) | OHSU Knight Cancer Institute | 2019-01-18 |
| JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia (NCT03557970) | OHSU Knight Cancer Institute | 2018-10-05 |
| Exercise Program Among Lung Cancer Dyads (NCT03649737) | OHSU Knight Cancer Institute | 2018-07-16 |
| Video Distraction to Decrease Use of Sedation in Pediatric Participants During Radiation Therapy (NCT03677531) | OHSU Knight Cancer Institute | 2018-05-31 |
| MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma (NCT03699995) | OHSU Knight Cancer Institute | 2018-05-18 |
| Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer (NCT03544125) | OHSU Knight Cancer Institute | 2018-05-03 |
| Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Locally Advanced Rectal Cancer (NCT03280277) | OHSU Knight Cancer Institute | 2018-04-27 |
| Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery (NCT03361436) | OHSU Knight Cancer Institute | 2018-03-19 |
| Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma (NCT03347617) | OHSU Knight Cancer Institute | 2017-12-20 |
| Nestle Impact Advanced Recovery in Improving Surgery Recovery in Patients With Head and Neck Cancer (NCT03261180) | OHSU Knight Cancer Institute | 2017-11-30 |
| Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases (NCT03325166) | OHSU Knight Cancer Institute | 2017-11-03 |
| Exercising Together During Radiation Treatment (NCT03418025) | OHSU Knight Cancer Institute | 2017-11-01 |